SET Nuclear Oncogene (SET) Peptide
SET
Reactivity: Human
Host: Rabbit
BP
-
- Target See all SET/TAF-I (SET) products
- SET/TAF-I (SET) (SET Nuclear Oncogene (SET))
- Origin
- Human
-
Source
- Rabbit
- Application
- Blocking Peptide (BP)
-
-
- Restrictions
- For Research Use only
-
- Storage
- -20 °C
-
- Target
- SET/TAF-I (SET) (SET Nuclear Oncogene (SET))
- Synonyms
- 2PP2A Peptide, I2PP2A Peptide, IGAAD Peptide, IPP2A2 Peptide, PHAPII Peptide, TAF-I Peptide, TAF-IBETA Peptide, 2610030F17Rik Peptide, 5730420M11Rik Peptide, AA407739 Peptide, I-2PP2A Peptide, StF-IT-1 Peptide, 2pp2a Peptide, i2pp2a Peptide, igaad Peptide, ipp2a2 Peptide, phapii Peptide, set Peptide, set-a Peptide, set-b Peptide, taf-ibeta Peptide, wu:fb30g11 Peptide, wu:fd16c08 Peptide, SET nuclear proto-oncogene Peptide, SET nuclear oncogene Peptide, SET translocation Peptide, SET nuclear proto-oncogene L homeolog Peptide, SET nuclear proto-oncogene b Peptide, SET Peptide, Set Peptide, LOC403555 Peptide, set.L Peptide, setb Peptide
- Background
- Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.
-
You are here:
